Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Company Overview

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Key Stats

• Today's Range: $40.00 to $40.00
• 50-Day Range: $39.78 to $40.31
• 52-Week Range: $15.25 to $43.00
• Volume: N/A
• Average Volume: 10,339 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.25
• Consensus Rating: Hold

Calliditas Therapeutics AB (publ) Stock Analysis - MarketRank™

Calliditas Therapeutics AB (publ) scored higher than 4% of companies evaluated by MarketBeat, and ranked 962nd out of 971 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Calliditas Therapeutics AB (publ) has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Calliditas Therapeutics AB (publ) has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Calliditas Therapeutics AB (publ) are expected to grow in the coming year, from ($0.99) to $4.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Calliditas Therapeutics AB (publ) is -21.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Calliditas Therapeutics AB (publ) is -21.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Calliditas Therapeutics AB (publ) has a P/B Ratio of 37.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CALT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Calliditas Therapeutics AB (publ) does not currently pay a dividend.

Dividend Growth

Calliditas Therapeutics AB (publ) does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CALT.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Calliditas Therapeutics AB (publ) has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Calliditas Therapeutics AB (publ) this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Calliditas Therapeutics AB (publ) is held by insiders.

Percentage Held by Institutions

Only 2.83% of the stock of Calliditas Therapeutics AB (publ) is held by institutions.

CALT Stock Analysis - Frequently Asked Questions

How have CALT shares performed this year?

Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 at the start of the year. Since then, CALT stock has increased by 55.4% and is now trading at $40.0001.
View the best growth stocks for 2024 here.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) issued its earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $52.36 million for the quarter, compared to analyst estimates of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%.

When did Calliditas Therapeutics AB (publ) IPO?

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Top institutional investors of Calliditas Therapeutics AB (publ) include Crossmark Global Holdings Inc. (0.05%).

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALT
• CUSIP: N/A
• CIK: 1795579
• Web: www.calliditas.se
• Phone: 46-0-841-130-05
• Fax: N/A
• Employees: 180
• Year Founded: 2004

Price Target and Rating

• Average Stock Price Target: $39.25
• High Stock Price Target: $40.00
• Low Stock Price Target: $39.00
• Potential Upside/Downside: -1.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,960,000.00
• Net Margins: -30.18%
• Pretax Margin: -29.40%
• Return on Equity: -212.04%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: 9.44
• Current Ratio: 2.69
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $1.60 billion
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 37.74

Miscellaneous

• Outstanding Shares: 29,790,000
• Free Float: 29,135,000
• Market Cap: $1.19 billion
• Optionable: Optionable
• Beta: 1.77